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Influence of health technology assessment and its measurement
Abstract
OBJECTIVES: The aim of this study was to obtain information on methods used to measure health
technology assessment (HTA) influence, decisions that were influenced, and outcomes linked to HTA.
METHODS: Electronic databases were used to locate studies in which HTA influence had been
demonstrated. Inclusion criteria were studies that reliably reported consideration by decision makers of
HTA findings; comparative studies of technology use before and after HTA; and details of changes in
policy, health outcomes, or research that could be credibly linked to an HTA. RESULTS: Fifty-one studies
were selected for review. Settings were national (24), regional (12), both national and regional (3)
hospitals (9), and multinational (3). The most common approach to appraisal of influence was review of
policy or administrative decisions following HTA recommendations (51 percent). Eighteen studies (35
percent) reported interview or survey findings, thirteen (26 percent) reviewed administrative data, and six
considered the influence of primary studies. Of 142 decisions informed by HTA, the most common types
were on routine clinical practice (67 percent of studies), coverage (63 percent), and program operation (37
percent). The most frequent indications of HTA influence were on decisions related to resource allocation
(59 percent), change in practice pattern (31 percent), and incorporation of HTA details in reference
material (18 percent). Few publications assessed the contribution of HTA to changing patient outcomes.
CONCLUSIONS: The literature on HTA influence remains limited, with little on longer term effects on
practice and outcomes. The reviewed publications indicated how HTA is being used in different settings
and approaches to measuring its influence that might be more widely applied, such as surveys and
monitoring administrative data.
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Abstract
Objectives: To obtain information on methods used to measure HTA influence, decisions that were influenced, and outcomes linked to HTA.
Methods: Electronic data bases were used to locate studies in which HTA influence had been demonstrated. Inclusion criteria were studies
that reliably reported consideration by decision-makers of HTA findings; comparative studies of technology use before and after HTA; and
details of changes in policy, health outcomes or research that could be credibly linked to an HTA.
Results: 51 studies were selected for review. Settings were national (24), regional (12), both national and regional (3), hospitals (9) and
multinational (3). The most common approach to appraisal of influence was review of policy or administrative decisions following HTA
recommendations (51%). Eighteen studies (35%) reported interview or survey findings, 13 (26%) reviewed administrative data and six
considered the influence of primary studies. Of 142 decisions informed by HTA the most common types were on routine clinical practice (67%
of studies), coverage (63%), and program operation (37%). Most frequent indications of HTA influence were on decisions related to resource
allocation (59%) change in practice pattern (31%) and incorporation of HTA details in reference material (18%). Few publications assessed the
contribution of HTA to changing patient outcomes.
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Conclusions: The literature on HTA influence remains limited, with little on longer term effects on practice and outcomes. The reviewed
publications indicated how HTA is being used in different settings and approaches to measuring its influence that might be more widely
applied, such as surveys and monitoring administrative data.

Keywords: Influence, impact, decision-making, health technology assessment
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Health technology assessment is used to inform decisions relating to health care systems. The effectiveness of an HTA program will depend on
its influence - the extent to which information provided in its publications has had an effect on decision makers and in what ways. In this
paper, HTA influence is considered to be any action or activity that can be credibly linked to information provided to a decision maker by an
assessment [1]. HTA influence is used rather than “HTA impact”, as representing a more realistic indication of the place of HTA in decisionmaking.
Information on the influence of HTA reports is a guide to the effectiveness of an assessment program. Such information is useful in reporting
to funders of HTA programs, in quality assurance processes, and in contributing to global indications of HTA achievements. In principle, there
will be interest in the influence of HTA on policy and administrative decisions, subsequent administrative action, delivery of health care and on
health status [1]. Much of the focus on HTA influence has been on the first of these. Subsequent administrative action is dependent on the
availability of effective machinery and the willingness of the decision maker to make use of it. Influence of an HTA report on subsequent action
and outcomes within a health care system depends on the actions of many individuals and organizations [1].
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There is still relatively little information available on the influence of HTA on health care decisions and their outcomes. Also, there is limited
detail available on methods used to assess HTA influence and the experience of HTA programs in applying such approaches. A review by
Gerhardus and Dintsios concluded there was little experience with study designs or methods that allow a valid assessment of the impact of
HTA reports on the decision making process. Only limited conclusions related to the impact of HTA reports could be drawn [2].
A review of policies and processes for the introduction of new interventional procedures into clinical practice identified seven studies that
described outcomes of policies [3]. The results showed that while the safety, efficacy and clinical and cost-effectiveness of new health
technologies are important considerations in the decision-making process, a number of other factors also play an important role. Decisions
were never based solely on the findings of HTAs. Niessen et al. [4] reported that 30 studies, including some on HTAs, found that use of
economic evidence had a “substantial” impact on health care policy making; 27 studies emphasized at least one other criterion. A further 11
studies found only a limited impact and two studies showed no impact.
The International Network of Agencies for Health Technology Assessment (INAHTA) had obtained information on HTA influence from its
members but had not reviewed the available literature. The network decided in 2012 that a working group would undertake a systematic
review of reports on HTA influence and its measurement. Five groups of either two or three reviewers were formed by working group
members to share the tasks of abstract selection and data extraction. The Swedish Council on Technology Assessment in Health Care (SBU)
undertook the literature review and provided project support.
6

A report on the review is available on the INAHTA website [5]. For this article on the review, the literature search was updated and additional
publications included. Further details were provided on the derivation of the categories used in reporting the review findings, and an
additional presentation linking details of technologies that were assessed with indicators of HTA influence. Material in the tables was updated
to reflect data from the additional studies and include percentages.
The objectives of the systematic review were to obtain information on the influence of HTAs on health care decisions and their outcomes, and
on the methods used to measure such influence.
METHODS
A protocol for the review was prepared by members of the working group. Broad inclusion criteria were specified covering studies reporting
consideration of HTA findings, and changes in policy, health technology use, health outcomes, or increased level of research.
Published literature was identified using PubMed, Embase, Cinahl , Cochrane Library, PsychInfo, NHSeed, HTA database, DARE, NHS Evidence,
and the Swedish HTA database. The searches were supplemented by hand searching the bibliographies of selected papers and through
contacts with HTA and other agencies. Publication dates were 2000 – August 2014, subsequently extended to November 2015. There were no
language restrictions. Search terms included Technology Assessment, Biomedical, HTA, systematic review, evidence-informed, impact,
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influence, information dissemination, implement, policy making, health policy and decision making. Further details of the literature search
strategy are available in the INAHTA report on the project [5].
Inclusion criteria were studies that reliably reported consideration by decision-makers of HTA findings and/or recommendations; comparative
studies that included relevant measures related to use of a health technology before and after dissemination of an HTA; and studies that
reported changes in one or more features that could be credibly linked to information provided by an HTA. Those features were policy related
to a health technology, use of a health technology in a health care system, relevant health outcomes associated with use of a health
technology, and an increased level of research or initiation of research. Expert opinion, correspondence, commentaries and duplicate
publications on the same study were excluded.
A data extraction form was developed, which included lists on approaches to assessing influence, types of decision, indications of HTA
influence and opinions on influence used in previous INAHTA publications [1, 6]. The form also included five indicators of study quality that
were specified in the protocol. These had some relevance to quality but were also related to the scope of a study (Supplementary List 1).
Quality ratings were given by the number of indicators that applied to each study, with scores from 1 to 5.
Each reviewer group was allocated a list of identified publications for initial screening using titles, abstracts and keywords. Any citations
considered relevant or for which there was uncertainty were retained at that stage and the full papers obtained. The identified publications
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were considered independently by the reviewer groups and selected if they met the inclusion criteria. Differences between individuals within
the reviewer groups were discussed and resolved by consensus.
Information extracted from the selected publications by the reviewer groups included the study setting, health technologies that were
assessed, types of decision informed by the assessment, the approach used to assess HTA influence, main indications of influence, measures
and/or opinion on influence, and non-HTA influences on outcomes. Any disagreements were resolved through discussion. For publications
covering many HTA reports, the technologies were listed but other elements in the data extraction were based on the summary information
that was provided, rather than considering each recommendation and its influence individually.
In some cases, the authors’ opinion on level of HTA influence was reported, or was apparent from details presented in the reviewed
publication. For other publications, a judgement on the level of influence was made by the reviewers. Level of influence was recorded on a
four point scale used in previous INAHTA projects (major influence on decisions, some input to decisions, some consideration of the
assessment, minimal influence) [6].
RESULTS
After removal of duplicates, 4,767 publications were identified by the literature search. An overview of publication selection is shown in
Supplementary Figure 1. Adjustments to initial selections were made through exclusion of earlier publications from series of reports on the
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same topic, papers that were not related to influence of HTA, and publications where there was insufficient information to provide a clear
indication of influence. Fifty five publications covering 51 studies were selected for review. Reports on measurement of HTA influence were
obtained from 19 countries – Argentina, Australia, Austria, Belgium, Canada, France, Finland, Germany, Italy, Malaysia, the Netherlands, the
PRC, Poland, Spain, Sweden, Switzerland, Thailand, the UK and the USA. Three publications provided information on more than one country a report on EU countries, a survey with details from Australia, Brazil, Canada, Spain and the USA, and a survey of Latin American and Caribbean
countries. Study settings were national (24), regional (12), both national and regional (3), multinational (3), and hospitals (9).
Approaches taken to appraisal of HTA influence are shown in Table 1. Several studies used more than one approach. The most common was
review of policy, and of acceptance of HTA recommendations (in 51% of studies). Eighteen studies (36%) used surveys or interviews with
decision makers, 13 (26%) reviewed or analysed administrative data, and six (12%) considered the influence of primary studies.
Types of decisions informed by the HTAs are shown in Table 2. Decisions related to routine practice (in 67% of studies), coverage (63%),
program operation (37%) and capital funding (35%) were the most common categories. Table 3 shows the indications of HTA influence that
were noted during data extraction. Several studies showed more than one influence on decisions. Influence on decisions involving resource
allocation was the most frequent indication (in 59% of studies). There were also a number of indications related to effects on practice (31%),
and incorporation of HTA details into reference material such as guidelines and program management manuals (18%).
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Opinion from 21 (41%) of the studies was that HTA had had a major influence on decisions. In 13 studies (25%) HTA had provided some input
to decisions, with 6 (12%) there was some consideration of the assessment and in 3 studies there was minimal influence. In the other 8
studies, details given indicated that HTA influence on decisions had varied for different technologies (major influence 80 (54%), input to
decisions 24 (16%), consideration of the assessment 36 (24%), minimal 9 (6%)). Some of the ‘minimal’ ratings were associated with the early
stages of HTA programs. Quality ratings were high (5 or 4) for 27 studies (53%). Seventeen (33%) had a rating of 3 and seven a rating of 2.
Brief details of material in the reviewed publications are shown in Table 4. Assessments on medical devices and surgical procedures informed
decisions on coverage and conditions of use for technologies, with consequences for routine practice. The studies on screening technology
point to the importance of HTA in providing input to government processes for the development and implementation of national screening
programs. HTAs had a major influence on coverage decisions for pharmaceuticals; there were limitations in the influence of negative
recommendations on the use of some drugs. The studies also indicated the place and value of rapid assessments and the success of hospital
HTA programs in influencing local policy and administrative decisions. Further information is presented in Supplementary Tables 1 and 2.
DISCUSSION
Both positive and negative HTA findings on health technologies were influential. Many related to relatively short- term targets (policy and
administrative decisions). Some also covered subsequent administrative action and program planning issues. Gerhardus and Dintsios [2] refer
to use of interviews with decision-makers, document analysis, surveys and use of administrative data as methods in the evaluation of HTA
11

influence. A similar mix of approaches was used by the studies included in this review, and also appraisal of the effects of primary studies.
Approaches using review of decisions seemed useful. Some HTA programs had close contact with decision makers, giving opportunities for
realistic appraisals.
The reviewed studies provide good examples of the place of HTA in health care decision-making. Information on the influence of assessments
can have a role in making a contribution to a broader, global perspective of HTA’s achievements and usefulness [1]. There were clear
indications of the benefits to both decision-makers and HTA researchers from maintaining regular, appropriate contact at all stages of the HTA
process (Supplementary Tables 1 and 2). For decision-makers there are examples of the sorts of decisions and programs that HTA informs.
There are some insights into the decision making process, and indications of savings, efficiencies and practice changes linked to HTA findings.
There are lessons to be learned from some limitations, both in consideration of HTA advice and in the implementation of decisions.
There were also examples that might be followed more widely on approaches to measuring influences. Valuable information on some longer
term influences was obtained through monitoring administrative data and through survey approaches. Primary studies can form a useful part
of the HTA process, as shown through indications of changes to practice patterns, relating to the delivery of health care [1].
There was little indication of influence of HTA on the health status of patients, though this was captured to some extent by a review of SBU
assessments. Two studies reported use of HTA linked to coverage with evidence development (CED) for consideration of policy decisions at
regional or national level. A CED approach was also used with an HTA program that evaluated surgical technologies. Estimates of savings
12

achieved through use of HTA were found in studies covering hospitals in Montréal and Buenos Aires, and in a study of HTA in Austria which
noted contributions to disinvestment decisions.
The literature covering the matters addressed by this review is still quite limited. Few recent studies have considered the influence of HTA in
any detail, and there is little on the longer term effects on clinical practice and health outcomes.
There is a progression of possible influence, from the decision maker level with increased knowledge and awareness, to changes in policy and
healthcare delivery, up to changes in patient outcomes. Changes to health care and improved health are dependent on the actions of many
individuals and organizations. Measuring change across all stages of influence should be considered, as the contribution of the HTA to changes
in patient outcomes is not going to occur if these earlier stages of influence have not first been realised.
Detailed appraisal of HTA influence, especially in the longer term, can become a significant research project. Such projects may be resource
intensive, and be undertaken only occasionally. Availability of data may be an issue; access to records may need to be negotiated, or surveys
of users of health technologies put in place. However, shorter - term evaluation of influence on decision makers may need only modest
resources. Essentially it is a question of incorporating approaches to obtaining indications of influence into the routine management of an HTA
program [1].
Both assessors and decision makers have important roles and responsibilities in the HTA process. Future studies on HTA influence will be
facilitated by good and continuing interaction between these parties. The HTA agency should aim to generate some reaction from decision
13

makers to the material and advice that have been provided. There should be contact with the decision makers early in the assessment process
and while the project is in progress. It is necessary to maintain a dialogue [62].
A monitoring system developed in Québec used telephone interviews with requesters and users to obtain reactions of decision makers to HTA
reports and intended action on the technologies that had been assessed [1]. Perceived relevance of recommendations and intention to adopt
recommendations can be used as a proxy for influence [62]. The INAHTA impact framework provides a basic approach to collecting
information on HTA influence [6]. Approaches based in part on application of the framework have been able to capture details of at least short
term influence [41]. Resources for more detailed studies on longer term influence of HTA should preferably be a matter for negotiation
between the assessment agency, its governance and decision makers at an early stage.
Further studies would also be facilitated by encouragement for agencies and their clients to give details of both successes and failures of their
HTAs in influencing decisions. ‘Failures’ as well as successes need to be considered and acted on if influence measurement is to be useful for
HTA program management, and as feedback to clients. Open provision and wide distribution by HTA programs of information on their
influence has been recommended [1].
This systematic review had several limitations. The estimated extent of influence is based on the authors’ findings and opinions, or on our to
some extent subjective judgements, and should be critically reviewed. We may expect some degree of publication bias towards positive
stories, but it is difficult to assess the extent of this. There were restrictions on the dates and scope of the literature search and on the
14

approach taken to assessment of study quality, to take account of time and resources available to reviewers. On the other hand, the quality
appraisal approach that was used touched on some things that are often not considered in a formal fashion. The information presented is
largely confined to summaries of details in the selected publications. There was not sufficient time to scan and follow up reference lists of
included publications or to carry out citation searching. For example, an overview by Raftery and Powell of the UK Health Technology
Assessment programme gives some indications of HTA influence that could be followed up [63]. Nor was it possible to systematically search
the grey literature for evaluations of HTA programs and their influence.
POLICY IMPLICATIONS
While there is variation in the influence that HTA reports or programs might have, most of the examples considered here informed decisions
on health technologies. All but three of the 51 studies identified successful HTA influence. HTA has been an important input to policy
formulation and implementation in many settings. The publications covered by this review have much useful information related to HTA
influence including approaches that might be used more often. Some of them had been produced as components of HTA program
management [1].
The limited number of studies following change in clinical practice and health outcomes indicates that these areas need much more attention
in the future. Quality registers and clinical data bases are growing rapidly around the world and they could be very useful tools for analysing
the influence of HTAs.
15
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Table 1: Approaches taken in assessing HTA influence *

Review of policy, and of acceptance of HTA recommendations

Number of studies

%

26

51

8

16

8

16

7

14

6

12

6

12

2

4

[10,12,14,18,21-24,26,28-32,36,38,39,41-46,48,50,51,57,60]
Questionnaire surveys of decision makers or agencies
[20,34,35,47,55,57,58,60,61]
Qualitative interviews with decision makers
[16,33-35,37,38,40,43,45,58]
Analysis of administrative data
[7,9,18,37,52,53,60]
Review of policy and of administrative data
[13,15,17,19,49,58]
Review of the effects of primary studies
[8,27,56-59]
Qualitative interviews plus review of decisions

26

[54,56]

* The numbers following each item denote the references
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Table 2: Types of decisions informed by HTA
Types of decision *
Influence on routine clinical practice

Number of studies %
34

67

32

63

19

37

18

35

14

27

12

24

6

12

[8,10,12-20,23,24,26,32,33,37,38,40-48, 52-58,60,61]
Coverage
[7,9,10,15-18,21,22,24-26,28,30-32,36-39,40-43,46,47,49-51,54-58,60,61]
Program operation
[9,12,17,18,2123,25,26,30,31,33,37,38, 40-42,44,48,55,56,60]
Capital funding
[13,16,19-21,27,38,40-45,47,48,50,54,55,61]
Guideline formulation
[7,8,11,13,14,29,34,35,40-42,55,57-61]
Indications for further research
[12,17,38,43,45,47,48,55,57,58,60,61]
Referral for treatment

28

[11,23,28,43,44,54]
Formulary

4

8

3

6

[38,43,49,55]
Other

a

a) Other decisions: Equipment sales [19], Legislation to regulate program [23], Strategy planning process [34, 35]
Table 3: Indications of HTA influence
Indication *
Acceptance of recommendations, linked to resource allocation

Number of studies %
30

59

16

31

9

18

6

12

[7,9-11,13-17,21-25,28,30,32,36,37,39-43,45-51,54]
Change in practice pattern
[8, 12,13,15,17-20,33,37,52,53,56-58,60]
Incorporation of HTA details in reference material
[29,34,35,40-42,47,55,58-60]
Planning process for program

29

[12,13,17,18,30,34,35]
Influence on research

4

8

3

6

Influence on other HTA programs [58,61]

2

4

Evaluation of device performance [27]

1

2

[12,17,44,60]
Acceptance of recommendations, clinical indications
[44,48,58]

30

Table 4: Details of technologies and HTA influence
Area

Topic

Indicators of HTA influence

Medical devices

Drug-eluting stents

* Available only for high-risk patients with abdominal aortic
aneurysm [7]

Peritoneal drainage catheter

*Availability for persons with recurrent malignant ascites [11]

Robotic surgery

*Agreement on indications and criteria for treatment [12]

Cochlear implantation

*Agreement on criteria for treatment [14] Decision not to
support bilateral CI for children [15]

Surgical devices

*Use by a purchasing organization for procurement decisions
[27]

Diagnostic services

Preoperative examinations

* Reduction in use of these services [19]

Pediatric radiology

* Effects of guidelines on practice patterns [8]

Pharmacogenomics in treatment of H.

* Determination that the technology was investigational [28]

pylori infection
Screening
technologies

Breast cancer

Acceptance of HTAs by governments, introduction of national
programs [17,18]
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Prostate cancer

* Recommendations against screening accepted, influence on
practice patterns limited by opportunistic testing [17,18]

Maternal screening in pregnancy

* Acceptance of HTAs by governments, introduction of
national programs [18,21,23] and a Ministry guideline [29]

Newborn screening

* Introduction and expansion of screening programs [30, 31].
* Coverage processes better when associated with HTA [22]

Abdominal aortic aneurysm screening

Surgical and other

* Service funded following HTA [26]

Disc arthroplasty

* Contributed to a decision on coverage following CED [9]

Hand transplantation

* Decision not to fund procedure [10]

Cardiac bypass surgery

* Expansion of open heart surgery services [24]

Treatment of severe morbid obesity

* Funding decisions on gastric banding and electrical

procedures

32

stimulation [30]
Prioritization procedures

* Decisions for cataract surgery, joint replacement [25]
bariatric surgery [26]

Respiratory disease

Approaches to management

* Changes in health services and clinical practice [33]

Public health

Tobacco prevention

* HTA program influenced dental professionals [20]

Planning for facilities and services

* HTAs influenced public health- related decisions [34,35]

National HTA

Coverage and other decisions, guidelines

* Acceptance of advice on coverage, disinvestment, guidelines

programs

and clinical practice

and practice patterns, influence on policy [36-38,46, 56-60]

Pharmaceutical coverage and use

* Major influence on coverage decisions [49-51]
* Changes in the level of use for management of blood
pressure, dyspepsia, multiple sclerosis [19] Negative appraisals
had little influence on drug use [52,53]

Regional HTA

Policy decisions based upon CED studies.

* Decisions consistent with HTA recommendations [39]

programs

Influence on ministry decisions

* Most HTAs influenced policy or program decisions [41,42]
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HTAs accepted by stakeholders [47]
Hospitals

Decisions in public hospitals

*Informed decisions on surgical technologies [44], new
technologies [45, 48], management of pediatric patients [13]

Other topics

Use of rapid HTAs

* Health ministry decisions were consistent with HTA advice
[54]. All HTAs had some influence [55].

Use of HTAs by other jurisdictions

* HTAs from other jurisdictions used to guide decisions [61]
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Supplementary Figure 1
Selection of publications

Records from search
screened after duplicates
removed
(n = 4,767)

Full-text articles assessed
for eligibility
(n = 219)

Records excluded
(n =4,548)

Records excluded
(n=169)
* Not related to HTA
influence (112)
*Insufficient
information provided
(41)

Records identified from
other sources, (n=5)
Publications included in
review
(n = 55 on 51 studies)

* Earlier reports on
the same topic (16)

Supplementary List 1: Indications of study quality

Answer the following questions (Yes/No) for each publication selected for review. Score
one point for each Yes answer and record the total score (maximum of 5). Higher scores
tend to indicate that greater confidence can be placed in the quality and applicability of the
study findings.
* Were the findings of the HTA report(s) summarized?
* Was the decision - making process that was influenced by the HTA described or
referenced?
* Was the approach used to assess HTA influence described?
* Were outcomes or influence reported?
* Were non – HTA influences considered?

Abbreviations used in Supplementary Tables 1 and 2

AAA: Abdominal aortic aneurysm
ACE: Angiotensin-converting enzyme
BCBS: Blue Cross and Blue Shield
BDa: Bone density measurement
CI: Cochlear implantation
CED: Coverage with evidence development
COtD: Chronic obstructive pulmonary disease
EU: European Community
HSR: Health services research
ICER: Incremental cost-effectiveness ratio
ICU: Intensive care unit
bHS: bational Health Service
bICE: bational Institute for Health and Care Excellence
OCT: Optical coherence tomography
tCR: tolymerase chain reaction
ttI: troton - pump inhibitor
tSA: trostate serum antigen
vALY: vuality–adjusted life year
SBU: Swedish Council on Technology Assessment in Health Care
SaS: Scottish aedicines Consortium
US: Ultrasound
Xpert aTB/RIF: aycobacterium tuberculosis and rifampicin resistance test

Supplementary Table 1. Publications covering HTAs and small numbers of technologies
Author,
Technology
Goeree [7], 2006
Drug-eluting
stents

Country/setting

Approach used

Canada, provincial
health system

Types of
decision
Coverage,
Guideline

Dunning [8],
2004
Skull X-ray, CT,
(paediatric)

England, three
hospitals

Guideline,
Practice

Sub analysis of prospective cohort
study, Monte-Carlo simulation

Schluessmann
[9], 2009
disc arthroplasty

Switzerland,
National

Coverage,
Program

Details of registry information
following decision to use CED

Brügger [10 ],
2014

Switzerland,
National

Coverage,
Practice

Details of a recommendation from
an appraisal of the HTA report and
subsequent consideration by the
national accident insurance
committee’

England, NHS

Referral,
Guideline

Formal decision process linked to
HTA findings

Hand
transplantation
White [11], 2012
peritoneal
drainage
catheter

Data on introduction and use
following HTA & decision maker
action

Indication of
influence
Acceptance of recommendations
re availability only for high-risk
AAA patients

Extent of
influence
Major

Guidelines do not increase
workload, but move patient
management from the
observation ward to the radiology
department
Coverage provided by insurance
program

Some input to
decisions

3

Major

5

Decision not to fund hand
Major
transplantation for
ethical reasons, because of
considerable side effects,
and relatively limited health gains,
particularly for unilateral
amputees
Acceptance of recommendation in Some
a Medical Technology Guidance
consideration

Quality
score
4

4

4

Supplementary Table 1 (continued)
Author,
Country/setting
Technology
Ballini [12],
Italy, Hospitals
2010
in the EmiliaRomagna
Robotic
Region and
surgery
regional health
authority
Demirdjian
[13 ], 2015
18 HTAs

Berrettini
[14], 2011
Cochlear
implantation
(CI)

Types of
decision
Program,
Practice,
Research

Approach used

Argentina,
national
pediatric
hospital

Capital
funding,
Guideline,
Program,
Practice

Monitoring decisions taken by
hospital administrators.
Review of administrative data

Italy, National
Agency for
Regional
Healthcare
Services,
coordinated by
Laszio Region

Guideline,
Practice

Advice re acceptance of
recommendations following
systematic review on clinical &
economic aspects of CI

Review of decisions following
evaluation by multidisciplinary
panel that included systematic
review, analysis of local
context, and identification
of indications with promising
clinical return.

Indication of
influence
Agreement on clinical indications for which the
robot should not be used and suspension of
these by hospitals and surgeons.
Agreement on a list of promising clinical
indications and for evaluation locally
Proposal by local surgeons, for two multicentre
clinical trials

Extent of
influence
Major

Quality
score
3

Acceptance of recommendations on:
* albumin solutions - albumin consumption
and associated costs reduced by 50%
* cochlear implantation a suitable device substituted
for one with unacceptable performance
* OCT - equipment was not incorporated
* palivizumab – use in high risk patients
* PCR – use in high risk patients
Not accepted on:
* reiki techniques (continued use in preoperative setting)
* procedural sedation program
Recommendations on criteria for treatment of
several patient groups were approved with
minimal suggestions by members of a
coordinating committee that represented all
stakeholders

Major

4

Some
consideration

2

Supplementary Table 1 (continued)
Author,
Country/setting
Technology
Kosherbayeva Kazakhstan,
National
[15 ], 2014
Bilateral
cochlear
implantation
for children
Vermeulen
[16], 2001
Screening –
breast cancer,
prostate
cancer,
ultrasound in
pregnancy
Banta [17],
2001
Screening –
a) breast
cancer,
b) prostate
cancer
c) ultrasound
in pregnancy

Types of
decision
Coverage,
Practice

Belgium,
Flemish
Preventive
Service

Coverage,
Capital
funding

Netherlands,
National

Coverage,
Program,
Practice,
Research

Approach used

Indication of influence

Extent of
influence
Some input
to decisions

Quality
score
4

Review of decisions by the
Ministry of Health following
systematic review on clinical
aspects of bilateral CI, and
analysis of administrative data
on hearing services in
Kazakhstan.
Interviews with stakeholders
and experts, review of policy

Ministry of Health decided not to support
provision of bilateral CI for deaf children.
Action would be taken to procure
equipment for early detection of children with
hearing loss, and to strengthen rehabilitation
services after unilateral CI.
Use of technologies did not follow advice from
available assessments. Lack of a systematic
approach to prevention policy and practice

Minimal

5

Appraisal of program
implementation, data on use
of screening tests

a) Mammography – CEA was followed by
national screening program for breast cancer
b) Recommended against prostate cancer
screening –, accepted by government but
“quite a lot” of opportunistic screening.
Recommendation re future research accepted
by ministry & implemented
c) Selective use supported, for high risk groups.
But 80 -90% pregnancies screened with US

a) & b) Major
c) Minimal

5

Supplementary Table 1 (continued)
Author,
Country/setting
Technology
Jonsson [18], 2001 Swedish public
hospital service
Screening –
a) breast cancer,
b) prostate cancer,
c) ultrasound in
pregnancy

Sweden - National
Britton [19], 2002
and local
a) Preoperative
(counties)
examinations
b) Management of
moderately
elevated blood
pressure,
c) Prostate cancer
screening.
d. Bone density
measurement
e. Neuroleptics as
calming therapy for
old persons
f. Proton pump
inhibitors for
functional
dyspepsia

Types of
decision
Coverage,
Program

Approach used

Indication of influence

Decisions and practice
patterns followed HTA
recommendations

Capital d,
Practice a,
b,c,e,g,
Equipment
sales d

Decisions/ trends in use
of technologies,
following HTA
recommendations

a) Strong influence on screening
mammography, rapid increase after
publication, all counties offered
screening.
b) HTA recommendations followed by
the county councils, none organised
screening programs for prostate cancer.
Opportunistic testing thought to be
relatively common and increasing in rate.
c) Introduction of routine screening was
recommended and became routine
a) Major decrease in pre- op exams
b) Levelling off in increase of ACE
inhibitor, calcium channel blocker
prescriptions
c) Huge increase in PSA test use
d) Increase in sales of BDM machines
e) Slow decrease in use of antipsychotic
drugs, larger in Kronoberg County which
made a concerted effort to reduce
f) National trend in prescriptions for PP
inhibitors unclear, overall cost for antidyspepsia drugs 8% less.
Decrease in PPI use in Skellefteå County
through local drug committee initiative

Extent of
influence
Major

Minimal : c,d)
Some
consideration:
b)
Some input to
decisions: e, g)
Major: a)

Quality
score
4

4

Supplementary Table 1 (continued)
Author,
Country/setting
Technology
Sweden, Dental
Axelsson [20],
hygienists &
2006
dentists in
Stockholm
Tobacco
County
prevention

Stemerding
[21], 2001
Maternal
screening
Fischer [22],
2011 Newborn
screening

Netherlands,
national

Autti-Ramo
[23], 2007
Fetal
abnormalities
screening

Finland, national

11 EU countries

Types of
decision
Practice

Approach used

Indication of influence

Questionnaire survey,
comparison with previous
investigation, reference to
SBU report and a guideline

Coverage,
Capital
funding,
Program
Coverage

Analysis of medical journals
and government reports

Awareness of guideline reported by 90%
hygienists, 66% dentists
Information in guideline used by 54%
hygienists, 34% dentists
25% of dental professionals reported
increased tobacco cessation consultation
However , no change in number of patients
receiving cessation support or the mean
time for these activities
Noted control and regulation of serum
screening by the political decision-makers,
allocation of funding. A counter influence
was promotion by the medical community,
Association between HTA and coverage
decision processes was more explicit,
inclusive, and transparent than non HTArelated decisions

Referral,
Program,
Practice,
Legislation to
regulate
program

Association between HTAs
and coverage decisions in EU
countries
7 decisions with HTA, 15
without
Relationship of decisions to
HTA recommendations

HTA provided information on options for
optimum screening programs, identified
major policy questions that required public
discussion. National committee
subsequently opened up this discussion

Extent of
influence
Some input
to decisions

Quality
score
5

Major

5

Some
consideration

3

Major
5

Supplementary Table 1 (continued)
Author,
Country/setting
Technology
Carlsson [24], 2001 Sweden,
national and
a) Cardiac bypass
local HTA
surgery
initiatives
b) Chiropractic
care for back pain
Gagnon [25], 2006
a. insulin pump
b. prioritization for
cataract surgery
c. prioritization
systems for hip or
knee replacement
Bergh [26], 2010
a) Bariatric surgery
b) Screening for
abdominal aortic
aneurysm
c) Liquid-based
cytology
d) Auricular
acupuncture for
drug addiction

Types of
decision
Coverage,
Practice

Approach used

Indication of influence

Review of administrative,
policy developments

Spain, hospitals
within Catalan
Health Regions

Coverage,
Program,
Practice

Semi-structured interviews,
transcripts classified
according to theoretical
dimensions and contextual
factors

a). HTA, other reports linked to
change in policy and expansion of
open heart surgery services
b). Results of RCT, including costs,
were input to decision by politicians at
local level (no difference in costeffectiveness)
Adoption of HTA recommendations
depends on a conjunction of factors
(institutional, organizational,
professional) that is unique to the
specific technology assessed.

Sweden, Västra
Götaland
County

Coverage
b,d,
Program
a,b,
Practice c

Review of HTA use by client
organizations,
implementation of
recommendations

a) Use by local authorities & regions
b) Funded and implemented
c) Widely recommended for screening
d) Coverage denied

Extent of
influence
Some input to
decisions

Quality
score
a) = 2
b)= 4

Some
consideration

3

Some
consideration:a,c)
Some input to
decisions: b,d)

2

Supplementary Table 1 (continued)
Author,
Country/setting
Technology
Burns [27], 2007
USA – Surgical
clip appliers,
practices
staplers, trocars,
suture and needle,
endoscopic
specimen retrieval
device

Types of
decision
Capital
funding

Approach used

Indication of influence

Evaluation by surgeons of
comparable medical devices
in standardized surgical
procedures, and use of
evaluation findings by a
hospital purchasing
organization

Products from 8 vendors evaluated
and ranked for ergonomics,
functionality, performance, clinical
acceptability.
1 vendor received consistently higher
ratings than the others across all
product categories; 2 received
consistently low ratings for several
product categories. Findings were
used by the purchasing organization
to select the vendor(s) they wished to
contract with
Policy statement that genotyping to
determine cytochrome p450
(CYP2C19) genetic polymorphisms is
considered investigational for
managing the treatment of H. pylori
infection. No change in 2011
Guidelines issued by the Ministry of
Health, based on HTA material

BCBS [28], 2008
Pharmacogenomics

USA, National

Coverage,
Referral

Review of policy response to
assessment

Chen [29], 2009
a) Assisted
reproductive
technology
b) Prenatal
diagnosis

PRC, National

Guideline,
Practice

Responses to contracted
assessments, action by the
Ministry of Health

Extent of
influence
Major

Quality
score
2

Major

2

Major

2

Supplementary Table 1 (continued)
Author,
Country/setting
Technology
Borowski [30],
Canada, Alberta
2007; IHE [31 ],
health ministry
2015
& health care
a) Laparoscopic
system
adjustable gastric
banding
b) Fetal
fibronectin assay
c) Gastric
electrical
stimulation
d) Newborn cystic
fibrosis screening
e) Newborn
metabolic
screening
Buxton [32], 2006
Interferons and
glatiramer
acetate for
multiple sclerosis

UK – England
and Wales

Types of
decision
Coverage (bd),
Program
(a,b,d,e),
Practice (d,e)

Approach used

Indication of influence

Formal decision process
linked to HTA findings,
review of health ministry
decisions

a) To be publicly funded; regions to
determine whether they will offer
bariatric surgery
b) Regions to introduce service and
determine best service delivery
model. All adopted the service.
Expected health system savings were
not achieved (reliance on falsepositive test results).
c) Not funded because of
investigational nature
d) Introduction of province-wide
screening, funding provided
e) Expansion of list from 3 to 16
conditions, funding provided

Coverage,
Practice

Example from review of
development of economic
evaluation of health
technologies in the UK and
its impact on decision
making

NICE deemed none of the drugs to be
cost effective at incremental cost per
QALY of £35 000–104 000.
Department of Health intervened with
scheme that accepted a
maximum threshold cost per QALY of
£36 000. If the patient’s progress
failed to equate with an ICER of
£36000 or less the cost of the drug to
the NHS would be rebated.

Extent of
influence
Major

Some input to
decisions

Quality
score
4

2

Supplementary Table 1 (continued)
Author,
Country/setting
Technology
Solans-Domènech
Spain – Catalan
[33], 2013
health system
a. Exacerbation of
COPD, - prognostic
factors
b) Risk factors
predisposing to
acute exacerbation
of COPD
c) Validation of a
diagnostic procedure
in sleep apneahypopnea syndrome,
d) Cost-effectiveness
of home care in
exacerbation
episodes of COPD
using a respiratoryfunction unit
e) Management of
bacterial resistance
in the ICU
f) Phenotypic
characterization of
COPD

Types of
decision
Program
Practice

Approach used

Indication of influence

Qualitative study of six
projects on respiratory
diseases funded between
1996 and 2004. Semistructured interviews with
15 researchers and 8
healthcare decision-makers

Most participants indicated changes in
health services or clinical practice had
resulted from research.
“The barriers and facilitators identified
were mostly organizational (in
research management, and clinical
and healthcare practice)…. Both the
expected and achieved impacts
enabled the identification of the gaps
between what is expected and what is
truly achieved.”
No specific recommendations for
policy makers;

Extent of
influence
Some input to
decisions

Quality
score
3

Supplementary Table 1 (continued)
Author,
Country/setting
Technology
UK – City:
Bowen 2007 [34],
strategies from
Opinion Leader
the Greater
Research [35], 2003
London
Authority (GLA)
Draft Economic
Development, Waste,
Energy, London Plan
strategies

Types of
decision
Guideline,
Strategy
planning
process

Approach used

Indication of influence

Qualitative strategy
to evaluate 4 health
impact assessments
(HIAs) of draft
mayoral strategies.
Included group
discussions, in depth
interviews,
questionnaires

Increased consultation
with public health staff
by GLA
Wider consultation
during development of a
strategy
Strategies were revised
as a result of outputs
from HIAs
Strategy team reported
few barriers to
incorporating
recommendations into
the final strategy
document.

Extent of
influence
Some input
to decisions

Quality
score
3

Supplementary Table 2: Publications on HTA programs and larger numbers of technologies
Author,
reports
Mad [36], 2012
25 HTAs + 9
updates

Zechmeister
[37], 2012
69 HTAs
including 11 full
reports

Vinck [38], 2013
78 reports
including HTAs,
HSR, Good
Clinical Practice

Country/setting
Austria, public
health care
system

Types of
decision
Coverage

Approach used

Indication of influence

Analysis of whether HTA advice
to regulate coverage was
accepted by the Ministry of
Health

HTAs recommended coverage with
limitations for 11 interventions and did
not recommend for 22. Ministry
decided on acceptance in 7 cases,
rejection in 18 and changed the status
to ‘subject to approval’ in 7
Findings from 9 of 11 full HTAs
contributed to decisions by insurance
funds and hospital management.
Recommendations from 19 of 42 rapid
assessments accepted by hospital
financing board.
Findings from 6 of 7 HTAs contributed
to disinvestment decisions which led to
savings of more than € 22 million
11 reports with recommendations
aimed at health care professionals
classified as “not measured”
About half of the remaining 67 reports
had a direct impact and about one third
were currently under discussion
In the case of one HTA report a decision
was taken that went directly against
recommendations

Austria, public
health care
system

Coverage,
Practice,
Program
management

Analysis of administrative data
from hospitals and
health insurance funds.
Interviews with representatives
of administrations and payers

Belgium National

Coverage,
Capital
funding,
Formulary,
Program,
Practice,
Research

Review of impact of reports
published during 2009-2011.
Information from project staff,
other contacts, websites,
legislation.
Direct impact if at least one
recommendation was
implemented; indirect impact if
recommendations featured in
debate but were not yet
implemented

Extent of
influence
Major

Quality
score
5

Some
input to
decisions

4

Major

5

Supplementary Table 2 (continued)
Author,
Country/setting
Types of
reports
decision
Coverage
Canada, Ontario
Levin [39],
public health care
2011
system
10 HTAs

Approach used

Indication of influence

Extent of influence

Consideration of policy
decisions based upon CED
studies. Compared decisions
with results of studies

In 9 cases decisions were
consistent with HTA
recommendations, awaiting
results for the other HTA

Major

a)Turnkey
[40], 2002
10 HTAs
Hailey [41,42]
2004, 2005
25 HTAs

Canada, Alberta
health system

Coverage,
Capital
funding,
Program,
Guideline,
Practice

a) Qualitative research interviews with HTA program
clients
b) Data collected by HTA
program using form in part
based on INAHTA instrument.

a) Eight of 10 products
informed policy and resource
allocation decisions.
b) Feedback from clients,
decisions on HTA
recommendations, inclusion of
HTA material in documentation

a)Some input to
decisions
b) 3 HTAs, had major
influence, 16 input
to decisions, 3 some
consideration, 3
minimal

McGregor
[43], 2012
20
technologies

Canada, University
Health Centre (five
teaching hospitals)
within the Québec
healthcare system.
Local in-hospital
HTA unit

Coverage,
Capital
funding,
Formulary,
Practice,
Research

Evaluation of the extent to
which reports have influenced
hospital policy decision making
and spending. Feedback from
individuals responsible for
technologies in question

Of 63 policy recommendations,
45 were accepted and
incorporated into Health Centre
policy. 1 was partially
incorporated, 17 were not
incorporated into policy.

Major influence on
the majority of
decisions, some
consideration for
others

Quality
score
4

a) 2
b) 5

4

Supplementary Table 2 (continued)
Author,
Country/setting
reports
Canada, Department of
Poulin [44],
Surgery & Surgical
2012
Services, Calgary Health
Surgical
Region
technologies
53 completed
applications for
support
Bodeau-Livinec France, Hospital network,
[45], 2006
Paris
13
technologies

Gibis [46], 2002
22
technologies

Germany, National –
committee responsible
for ambulatory health
care (legally binding
directives)

Types of
decision
Capital
funding,
Program,
Practice,

Approach used

Indication of influence

Extent of
influence
Some input
to
decisions

Quality
score
4

Retrospective analysis on
outcomes of a local HTA
program over 5 years
Local HTA committee
decisions categorised

12 applications approved, 3 approved
for a single case on an urgent basis, 21
approved for a restricted number of
cases with outcomes review, 14 for
research use only, 3 referred to
additional review bodies.

Capital
funding,
Practice,
Research

a) Qualitative – semi
structured interviews with
persons affected by HTA
recommendations
b) Review of decisions
following 13 HTAs

7 Major influence, usually through
funding being approved or withheld
3 difficult to distinguish between HTA
influence and that of experience gained
during supplementary studies
1 Minimal influence , decision contrary
to recommendation
2 uncertain due to influence of major
external factors

1 Minimal
7 Major
5
Uncertain

5

Coverage,
Practice

Considered whether HTA
recommendations were
accepted by the
committee

The committee decisions were
consistent with HTA recommendations

Major

2

Supplementary Table 2 (continued)
Author,
Country/setting Types of decision
reports
Norezam [47],
Malaysia, Public Coverage,
2013
hospitals
Capital funding,
Overall output
Practice,
from HTA agency
Research
responses for
management of
diabetes mellitus
and
thalassaemia, CT
for head injury,
US in primary &
antenatal care,
moderately
elevated blood
pressure
Capital funding,
Australia,
Ju [48 ], 2014
Program,
Queensland
Practice,
hospitals
35 HTAs
Research

Approach used

Indication of influence

Extent of
influence
Some
input to
decisions

Survey of persons in
public hospitals, health
departments, research
institutes and Ministry
of Health.

% participant responses:
Recommendations/ conclusions
accepted : 83%
Showed technology met program
requirements: 79%
Material incorporated into policy
documents: 69%
Used as reference material: 78%
Linked to change in policy: 75%

Review of HTA decisions
and their
implementation

19 HTAs recommended funding for
Major
piloting of the technologies; this had
commenced for 17 with final decision
pending for 2. (e.g. greenlight laser
therapy, electromagnetic navigation
bronchoscopy, Xpert MTB/RIF,
excimer laser system)
Funding not recommended for 7
technologies (e.g. percutaneous
microwave ablation, robotic
navigation system)

Quality
score
3

3

Supplementary Table 2 (continued)
Author,
Country/setting
reports
Kolasa [49], 2011 Poland, National
health system
151 drug
therapies

Types of decision

Approach used

Indication of influence

Coverage,
Formulary

Reimbursement lists
reviewed to assess to
what extent policymakers had used the
information coming
from the HTAs

34 drugs appraised and reimbursed
(4 negative and 30 positive HTA
recommendations)
117 appraised and not reimbursed
(58 positive and 59 negative
recommendations)

France, National

Coverage

Review of Ministry &
sickness fund decisions
following HTA
recommendations

Teerawattananon Thailand,
National – public
[51 ], 2014
health insurance
program

Coverage

Review of decisions by
Subcommittee for
development of the
National List of Essential
Medicines on
recommendations for
inclusion of medicines
in the list, based on
economic and other
assessments.

> 95 % of positive HTA opinions on
reimbursement status of a new
technology were followed by
decisions to reimburse. Almost all
negative opinions were followed.
1999 – 2001: concluded 835 of 4,490
medicines showed insufficient
benefit, reimbursement rates were
reduced
2003 – 06: proposed delisting 370,
322 were delisted, decision to retain
48 drugs for cerebral insufficiency in
the elderly population.
Ten medicines were accepted for
inclusion in the national list, 11 were
excluded and one was under price
negotiation

Rochaix [50],
2009
Large numbers of
drugs

Extent of
influence
Some
input to
decisions

Quality
score
3

Major

3

Some
input to
decisions

3

Supplementary Table 2 (continued)
Author,
Country/setting
reports
Scotland – National
Bennie [52],
Health Service
2011
Medicines
that the
Scottish
Medicines
Consortium
(SMS)
had not
recommende
d for use
UK - ambulatory care
Dietrich [53],
of the NHS in England
2009
and Wales
34 drugs with
negative
technology
appraisal
recommendat
ions or
positive ones
with major
restrictions
Hailey [54],
2000
20 rapid HTAs

Types of decision

Approach used

Indication of influence

Practice

Analysis of effect of
advice from the SMS on
use of medicines.
Volume of prescribing
measured by each
medicine’s gross
ingredient cost to the
prescribing budget

Data were available for 8 of 10
medicines not recommended for use.
Use increased for 5 medicines,
stabilized for 2 and decreased for 1.
(Data show that use of one medicine
categorized as ‘stabilized’ had
increased)

Practice

Secondary analysis
from the prescription
costs analysis statistics
and comparison with
NICE recommendations

For 97 % of the drugs, the publication
of NICE's 14 negative and restricting
technology appraisals between 2000
and 2004, did not reduce the number
of prescription items dispensed or
net ingredient costs in the
ambulatory care of the NHS

Minimal

Interviews and written
feedback with
requestors of HTA or
persons who might be
influenced by the
findings

Decisions by health ministry
consistent with HTA advice. Two
HTAs had no apparent influence.

14 Major
4 Some
consideration
2 Minimal

Canada, Alberta health Coverage,
system
Capital funding,
Referral,
Practice

Extent of
influence
Minimal

Quality
score
4

4

Supplementary Table 2 (continued)
Author,
Country/setting
reports
Australia, Brazil,
Hailey [55],
Canada, Spain, USA –
2009
health ministries or
departments
15
technologies

Oortwijn [56],
2008
HTA research
programs in
detection of
cancer
metastases,
mental &
behavioural
disorders,
care of
chronically ill,
clinical
genetics,
infectious
diseases, PET,
treatment of
fertility
disorders

Netherlands, various
primary studies
supported by the
Dutch HTA program

Types of decision

Approach used

Indication of influence

Coverage 9,
Capital funding 1,
Formulary 1,
Referral 2,
Program 2,
Guideline 3,
Practice 3,
Research 2
Program,
Practice

Survey of INAHTA
members on rapid
HTAs that they had
prepared during 2006.

All the HTAs were considered to have
had some influence. Most common
indications were consideration by the
decision maker, use of the HTA as
reference material (both n = 10), and
acceptance of recommendations or
conclusions (n = 8).

Case studies using
“payback framework”.

Authors comment that “it is too early
to fully assess impact of the Dutch
HTA program”
Details might provide a baseline for
future appraisal of payback
Two examples of changes in practice
One example of informing policy for a
local insurer

Extent of
influence
8: Major
7: Some
consideration

Quality
score
4

Some
consideration

3

Supplementary Table 2 (continued)
Author,
Country/setting
reports
UK – NHS England &
Hanney [57],
Wales
2007
9 primary
studies, 4
secondary
studies, 3 NICE
technology
assessment
reviews (TARs)
Guthrie [58 ],
2015
Publications
from studies
funded by an
HTA programme

UK – NHS England &
Wales

Types of
decision
Coverage,
Guideline,
Practice,
Research

Approach used

Indication of influence

Review of first 10 years of NHS HTA
Programme, included
questionnaire survey of lead
investigators and 16 case studies.
Analysis using payback framework

Coverage,
Guideline,
Practice

Review of NHIS HTA Programme
from 2003-2013. Interviews with
20 senior stakeholders
Electronic survey of HTA grant
holders.
12 payback case studies
of HTA programme-funded
research.

Concluded programme had
perceived impact on policy and
to some extent on practice. 73%
of survey respondents claimed
projects had impacted on policy
and 56% on behaviour (96% for
TARs)
11 of 16 case studies thought to
have made some impact on
policy
*Interviews indicated the
primary route to impact of
programme-funded research on
patients is through influence on
guidelines.
* Survey responses for 93 HTA
program projects reported an
impact on policy, including
citation in guidelines and other
documents.
* 7 out of 12 case studies
provided some evidence
research had an impact on the
NHS and patients, and 4
included limited evidence of
changes in clinical practice.

Extent of
influence
Major

4

Major

3

Quality
score

Supplementary Table 2 (continued)
Author,
Country/setting
reports
UK – NHS England &
Turner [59 ],
Wales
2015

Types of
decision
Guideline

122 NICE clinical
guidelines,
issued between
April 2001 and
April 2012

Rosén [60], 2014
26 reports from
2006-10

Sweden - National
and regional
(counties)

Program,
Guideline,
Practice,
Research

Approach used

Indication of influence

Retrospective cohort study,
proportion of NICE guidelines
which cited evidence from studies
funded by the NIHR HTA
Programme and the impact of
those studies on the guidelines

Of 122 guidelines, 3 (2%) were
based on previous NIHR HTA
reports and 90 (74%) cited
evidence from NIHR HTA studies.
The impact of HTA evidence on
the guidelines varied; the ways in
which data was used by NICE was
heterogeneous. There was
extensive use of NIHR-HTA data
in guidelines on Chest Pain of
Recent Onset, The Epilepsies and
Chronic Heart Failure.
Decisions and actions of national Major
and local government bodies,
and of professional
organizations. Changes in use of
technologies and services.
HTA reports had a high impact
on clinical guidelines, and a
moderate or high impact on
comprehensive decisions,
initiation of research and
changes in clinical practice.
Impact was low in three cases.

Measured the extent to which HTA
reports had affected decisions,
guidelines, research or clinical
practice. Used documentation,
before-after surveys and time
series register data.

Extent of
influence
Some input
to decisions

Quality
score
3

4

Supplementary Table 2 (continued)
Author,
Country/setting
reports
19 Latin American &
Pichon-Riviere
Caribbean (LAC)
[61], 2012
countries, 55%
HTAs from other responses were
from Argentina
jurisdictions

Types of decision

Approach used

Indication of influence

Coverage,
Capital funding,
Guideline,
Practice,
Research

Survey of decision makers and
researchers on HTA
transferability experiences

Decision makers reported
using HTAs from other
jurisdictions to guide
decisions in the majority of
cases:
52.6 % HTAs from outside LAC
23.1 % from other LAC
countries,
24.3 %HTAs from their own
countries.
63 % of researchers reported
using HTAs from other
jurisdictions; information
regarding safety and
effectiveness was considered
more applicable than that on
social aspects, or economic
evaluation

Extent of
influence
Some
consideration

Quality
score
3

